Skip to main content

Table 1 Main characteristics of the included studies

From: Tumor-associated tissue eosinophilia predicts favorable clinical outcome in solid tumors: a meta-analysis

Study

Year

Tumor type

No. of Patients

Male/Female

median age (range) (year)

Staining

TATE: Present / absent

Tumor stage

median follow-up date (months)

Survival

Quality Score (NOS)

Peurala, E. etal [15]

2018

Oral cancer

99

55/44

65.3

H&E

51/47

I - III

40.7

OS

8

Oliveira, D. T. etal [16]

2012

Oral cancer

71

55/16

59 (35, 77)

H&E

35/36

I - II

NR

DFS

7

Tostes Oliveira, D. etal [19]

2009

Oral cancer

43

27/16

55.79 (28, 83)

H&E

21/22

I - IV

(3, 229)

OS

7

Dorta, R. G. etal [17]

2002

Oral cancer

125

105/20

58 (30, 95)

H&E

57/68

II - III

88.2 (0, 287.4)

OS, DFS

7

Dante, P. etal [40]

2019

Tongue Carcinoma

259

223/36

53.0 ± 12.2

H&E

NR

I - IV

NR

OS, DFS

8

Alrawi, S. J. etal [18]

2005

Head and neck carcinoma

87

NR

(41, 76)

H&E

13/7

II - IV

36 (6, 216)

OS, DFS

7

Ercan, I. etal [20]

2005

Laryngeal carcinoma

78

78/0

55.9 (35, 80)

H&E

25/53

NR

41.91

OS

7

Sassler, A. M. etal [21]

1995

Laryngeal carcinoma

248

NR

NR

H&E

56/192

III - IV

48

OS, DFS

6

Thompson, A. C. etal [22]

1994

Laryngeal carcinoma

104

85/19

64.6 (39, 91)

H&E

31/73

NR

≥ 60

OS

6

Fujii, M. etal [23]

2002

Nasopharyngeal carcinoma

53

40/13

49.4 (15, 81)

H&E

26/27

I - IV

90.5 (35.3, 199.9)

DFS

7

Leighton, S. E. etal [24]

1996

Nasopharyngeal carcinoma

96

68/28

NR

H&E

65/31

NR

57

OS, DFS

6

Harbaum, L. etal [25]

2015

Colorectal cancer

381

166/215

68.5

H&E

101/280

I - IV

45 (1, 182)

OS

8

Fernandez-Acenero, M. J. etal [26]

2000

Colorectal cancer

126

70/56

67.35 (32, 87)

H&E

29/97

Duke’s A-C

≥ 60

OS, DFS

8

Nielsen, H.J. etal [27]

1999

Colorectal cancer

584

240/344

61 (49, 75)

H&E

150/115

Duke’s A-D

61 (49, 75)

OS

7

Prizment, A. E etal [28]

2016

Colorectal cancer

441

0/441

(55, 69)

H&E; EPX

197 /244

NR

60

OS

8

Zhang, Y. etal [29]

2014

Esophageal carcinoma

36

25/11

59 (45, 77)

H&E

18/18

I - IV

22 (2, 143)

OS

7

Ishibashi, S. etal [30]

2006

Esophageal carcinoma

97

82/15

62.7 ± 8.9

H&E

30/31

NR

61.7 (5.3, 165.4)

OS

7

Hollander, P. etal [31]

2018

Hodgkin’s lymphoma

459

242/217

< 45: 68%; ≥45: 32%

H&E

NR

I - IV

154.8

OS

8

Kereszres, K. etal [32]

2007

Hodgkin’s lymphoma

104

54/50

33 (12, 72)

H&E

64/40

I - IV

110 (24, 214)

OS, DFS

7

von Wasielewski, R. etal [33]

2000

Hodgkin’s lymphoma

1511

745/766

(15, 75)

H&E

510/823

I - IV

120

OS

8

Enblad, G.etal [34]

1993

Hodgkin’s lymphoma

140

NR

45 (11, 94)

H&E

26/114

I - IV

48 (20, 85)

DFS

6

van Driel, W.J. etal [35]

1996

Cervical cancer

83

0/83

42.1

H&E

NR

I - IIA

44.6 (5, 108)

OS, DFS

7

Bethwaite, P. B. etal [36]

1993

Cervical cancer

67

0/67

43.7 (25, 76)

H&E

28/39

IB

62.4 (1, 93)

OS

7

Flamm, J. etal [37]

1992

Bladder cancer

428

289/139

70.2 (29, 91)

H&E

99/329

NR

84

OS

7

Iwasaki, K. etal [38]

1986

Gastric cancer

647

364/283

(22, 84)

H&E

157/490

I - IV

(8, 92)

OS

7

Ono, Y. etal [39]

2002

Penile cancer

17

17/0

68 (36, 84)

H&E

9/8

I - IV

NR

OS

6

  1. H&E haematoxilyn and eosin, EPX eosinophil peroxide, NR not reported